PL4011898T3 - Pochodna 3-hydroksy-5-pregnan-20-onu i jej zastosowanie - Google Patents
Pochodna 3-hydroksy-5-pregnan-20-onu i jej zastosowanieInfo
- Publication number
- PL4011898T3 PL4011898T3 PL20852240.9T PL20852240T PL4011898T3 PL 4011898 T3 PL4011898 T3 PL 4011898T3 PL 20852240 T PL20852240 T PL 20852240T PL 4011898 T3 PL4011898 T3 PL 4011898T3
- Authority
- PL
- Poland
- Prior art keywords
- pregnane
- hydroxy
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910736020.8A CN112341511A (zh) | 2019-08-09 | 2019-08-09 | 3-羟基-5-孕烷-20-酮衍生物及其用途 |
| PCT/CN2020/107965 WO2021027744A1 (zh) | 2019-08-09 | 2020-08-07 | 3-羟基-5-孕烷-20-酮衍生物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4011898T3 true PL4011898T3 (pl) | 2026-05-11 |
Family
ID=74366997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20852240.9T PL4011898T3 (pl) | 2019-08-09 | 2020-08-07 | Pochodna 3-hydroksy-5-pregnan-20-onu i jej zastosowanie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220289788A1 (pl) |
| EP (1) | EP4011898B8 (pl) |
| JP (1) | JP7785674B2 (pl) |
| CN (2) | CN112341511A (pl) |
| DK (1) | DK4011898T3 (pl) |
| ES (1) | ES3060711T3 (pl) |
| FI (1) | FI4011898T3 (pl) |
| PL (1) | PL4011898T3 (pl) |
| PT (1) | PT4011898T (pl) |
| RS (1) | RS67876B1 (pl) |
| WO (1) | WO2021027744A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114907436A (zh) * | 2021-02-08 | 2022-08-16 | 南京诺瑞特医药科技有限公司 | 3-羟基-5-孕烷-20-酮衍生物的晶型及其制备方法和用途 |
| CN115806579B (zh) * | 2021-09-14 | 2025-10-24 | 南京迈诺威医药科技有限公司 | 一种水溶性别孕烷醇酮衍生物及其制备方法和用途 |
| IT202100030671A1 (it) | 2021-12-03 | 2023-06-03 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI (3a,5a)-20-OSSOPREGNAN-3-IL GLICIL-L-VALINATO CLORIDRATO |
| CN117801047B (zh) * | 2023-01-19 | 2024-12-20 | 北京华睿鼎信科技有限公司 | 神经甾体衍生物及其用途 |
| WO2024188169A1 (zh) * | 2023-03-10 | 2024-09-19 | 南京迈诺威医药科技有限公司 | 别孕烷醇酮衍生物的盐型、多晶型及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| DK0752860T3 (da) * | 1994-02-14 | 2000-11-13 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| CA2582231A1 (en) * | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Steroid analogs and uses |
| AU2009219230A1 (en) * | 2008-02-26 | 2009-09-03 | Emory University | Steroid analogues for neuroprotection |
| GB2470700B (en) * | 2008-03-25 | 2012-08-08 | Univ Maryland | C-17 heteroaryl steroidal CYP17 inhibitors |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| WO2010088409A2 (en) * | 2009-01-30 | 2010-08-05 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| BR112012017136B1 (pt) * | 2010-01-14 | 2021-05-25 | Umecrine Mood Ab | composição farmacêutica compreendendo 3-beta-hidróxi5-alfa-pregnan-20-ona, colesterol e uma mistura de acilgliceróis, método para preparar dita composição farmacêutica, bem como usos da mesma para o tratamento ou prevenção de condições do sistema nervoso central e para cessar a anestesia induzida por esteroide |
| WO2011120044A1 (en) * | 2010-03-26 | 2011-09-29 | Duke University | Conjugated neuroactive steroid compositions and methods of use |
| US9670247B2 (en) * | 2012-07-02 | 2017-06-06 | The University Of Kansas | Contraceptive agents |
| WO2015081170A2 (en) * | 2013-11-26 | 2015-06-04 | Systamedic Inc. | Ganaxolone derivatives for treatment of central nervous systems disorders |
| CN103772469A (zh) * | 2014-02-21 | 2014-05-07 | 中国科学院上海有机化学研究所 | 一种含有动物固醇和天然精氨酸结构片段的合成阳离子脂质、合成方法及其应用 |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN108148106A (zh) * | 2016-12-05 | 2018-06-12 | 江苏恩华络康药物研发有限公司 | 一类水溶性别孕烯醇酮衍生物及其用途 |
| US20200276211A1 (en) * | 2017-11-28 | 2020-09-03 | Viewpoint Therapeutics, Inc. | Compounds for treating near vision disorders |
| CN108517001A (zh) * | 2018-05-17 | 2018-09-11 | 江苏恩华络康药物研发有限公司 | 水溶性别孕烯醇酮衍生物及其用途 |
| CN109776647B (zh) * | 2019-02-14 | 2021-09-17 | 烟台大学 | 具有抗炎活性的Pyxinol酯化衍生物及其制备方法和应用 |
| CZ309617B6 (cs) * | 2019-04-05 | 2023-05-24 | Ústav organické chemie a biochemie AV ČR, v. v. i | 3α5ß-Neuroaktivní steroidy pro léčbu epilepsie a záchvatových onemocnění |
-
2019
- 2019-08-09 CN CN201910736020.8A patent/CN112341511A/zh active Pending
-
2020
- 2020-08-07 PL PL20852240.9T patent/PL4011898T3/pl unknown
- 2020-08-07 JP JP2022534483A patent/JP7785674B2/ja active Active
- 2020-08-07 CN CN202080054158.0A patent/CN114206899B/zh active Active
- 2020-08-07 EP EP20852240.9A patent/EP4011898B8/en active Active
- 2020-08-07 PT PT208522409T patent/PT4011898T/pt unknown
- 2020-08-07 ES ES20852240T patent/ES3060711T3/es active Active
- 2020-08-07 WO PCT/CN2020/107965 patent/WO2021027744A1/zh not_active Ceased
- 2020-08-07 RS RS20260316A patent/RS67876B1/sr unknown
- 2020-08-07 FI FIEP20852240.9T patent/FI4011898T3/fi active
- 2020-08-07 US US17/632,770 patent/US20220289788A1/en active Pending
- 2020-08-07 DK DK20852240.9T patent/DK4011898T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7785674B2 (ja) | 2025-12-15 |
| EP4011898B1 (en) | 2026-01-07 |
| CN112341511A (zh) | 2021-02-09 |
| EP4011898A1 (en) | 2022-06-15 |
| WO2021027744A1 (zh) | 2021-02-18 |
| ES3060711T3 (en) | 2026-03-27 |
| DK4011898T3 (da) | 2026-03-09 |
| JP2022545047A (ja) | 2022-10-24 |
| PT4011898T (pt) | 2026-03-25 |
| EP4011898B8 (en) | 2026-02-18 |
| CN114206899A (zh) | 2022-03-18 |
| CN114206899B (zh) | 2025-09-05 |
| RS67876B1 (sr) | 2026-04-30 |
| EP4011898A4 (en) | 2023-09-20 |
| FI4011898T3 (fi) | 2026-02-24 |
| US20220289788A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278171A (en) | Glucose-dependent insulin polypeptide and its uses | |
| IL294052B2 (en) | Fluoroalkyl oxadiazoles and their uses | |
| IL285177A (en) | compounds and their use | |
| IL286497A (en) | compounds and their use | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL277502A (en) | Compounds and uses for them | |
| IL293980B1 (en) | New compounds and their use | |
| IL277749A (en) | Palladianolide compounds and their use | |
| IL291499A (en) | Azaquinoline compounds and their uses | |
| PL3858833T3 (pl) | Pochodna aminonorbornanu oraz sposób jej wytwarzania i zastosowanie | |
| ZA202105752B (en) | Haloallylamine compounds and application thereof | |
| IL284994A (en) | Pyrrolopyrimidine derivative and its use | |
| EP4011898B8 (en) | 3-hydroxy-5-pregnane-20-one derivative and use thereof | |
| IL287503A (en) | Thio-semicarbazide compounds and their use | |
| IL282527A (en) | 5-Azaindazole history and their use | |
| IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
| IL284764A (en) | compounds and their uses | |
| GB201801102D0 (en) | New compounds and uses | |
| IL279483A (en) | Cyanotriazole compounds and their uses | |
| IL275935A (en) | Its use and its derivative | |
| SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
| IL282526A (en) | 5-Azaindazole history and their use | |
| IL280644A (en) | Magnesium serine compound and its use | |
| GB2589437B (en) | Circuitry and methods | |
| IL288828A (en) | Binding factors - cd38 and their use |